Is Avonib included in domestic medical insurance?

Ivosidenib is a targeted therapy drug mainly used to treat patients with acute myeloid leukemia (AML) who carry isocitrate dehydrogenase1 (IDH1) mutations. As a drug that specifically targets IDH1 mutations, ivonib blocks the abnormal metabolic pathways of cancer cells by inhibiting the activity of IDH1 enzymes, thereby effectively curbing tumor growth. This targeting mechanism enables ivonib to demonstrate significant efficacy in the treatment of AML patients, especially those who are insensitive to or have developed resistance to traditional chemotherapy.

Although ivonib has been launched in China, bringing new treatment options to Chinese patients, this drug has not yet been included in the reimbursement scope of the national medical insurance. For patients, this means that they need to pay for ivonib out of pocket, which undoubtedly increases the financial burden of treatment. According to market information, the domestic selling price of Avonib is approximately RMB 30,000 to RMB 40,000 per box. Due to the high price, many patients need to carefully consider financial factors before treatment, and it is recommended to consult the local hospital pharmacy to obtain accurate price information before purchasing drugs.

Because ivonib is not reimbursed by medical insurance, many patients face huge financial pressure. In this case, foreign generic drugs have become a more economical alternative. In particular, generic drugs from Laos have attracted attention in the market due to their lower prices and relatively stable supply. The price of generic drugs in Laos is about 6,000 to 7,000 yuan, which is much cheaper than domestic original drugs. Although the price difference is significant, Lao generic drugs are basically the same as the original drugs in terms of drug ingredients and efficacy, providing patients with a relatively economical treatment option.

In short, although ivonib is an important drug for the treatment of IDH1mutatedAML patients in China, its high price and the fact that it is not covered by medical insurance put patients under certain financial pressure during the treatment process. For patients with limited financial conditions, considering foreign generic drugs may be a more feasible option. When choosing a treatment plan, it is recommended that patients fully communicate with their doctors and choose the most suitable treatment path based on their own financial situation and condition.